Filing Flows › RenovoRx (RNXT) › Q2 2026 › vs Q2 2025
RenovoRx (RNXT) Q2 2026 vs Q2 2025 (year over year)
RenovoRx's revenue rose $487K (+115%) from $422K in Q2 2025 to $909K in Q2 2026.
RenovoRx, Q2 2026: revenue $909K (+115% year over year), operating margin -368.4%, net loss $2.9M, operating cash flow −$2.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $909K | $422K | $487K | +115% |
| Other income, net | $438K | −$217K | $655K | — |
| Net loss | $2.9M | $2.9M | $16K | +0.6% |
| Costs & expenses | $4.3M | $3.3M | $941K | +28% |
| Operating costs | $4.3M | $3.1M | $1.2M | +37% |
| Cost of revenue | $143K | $152K | −$9K | -6% |
| Research & development | $1.2M | $1.4M | −$226K | -16% |
| SG&A | $2.9M | $1.5M | $1.4M | +92% |
| Operating cash sources | $3.4M | $3.6M | −$205K | -6% |
| Depreciation | $5K | $1.0M | −$995K | -100% |
| Share-based compensation | $570K | $345K | $225K | +65% |
| Cash used in operations | $2.9M | $2.3M | $565K | +25% |
| Net loss absorbed | $2.9M | $2.9M | $16K | +0.6% |
| Working capital & other | $531K | $752K | −$221K | -29% |
Questions
How much did RenovoRx's revenue grow year over year in Q2 2026?
RenovoRx's revenue rose $487K (+115%) from $422K in Q2 2025 to $909K in Q2 2026.